A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of post-ureteroscopy health care ...
This digital series features articles and videos with insights and expert viewpoints on PSMA-PET and the evolving imaging paradigm that is revolutionizing the diagnosis and treatment of patients with ...
In this episode, Anup A. Vora, MD, discusses patient selection for focal therapy in localized prostate cancer, the role of precision medicine, and how advanced practice providers are helping deliver ...
Talazoparib plus enzalutamide significantly improved OS in HRR-deficient and unselected mCRPC patients compared to enzalutamide alone. The FDA approved the combination for HRR-gene mutated mCRPC but ...
Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...
Detalimogene voraplasmid is a non-viral gene therapy for high-risk NMIBC, aiming to elicit an anti-tumor immune response. The LEGEND trial's pivotal cohort has enrolled 100 patients, with updates ...
CAN-2409 plus valacyclovir significantly improved DFS in localized intermediate- to high-risk prostate cancer, showing a 30% improvement over standard care. The treatment enhanced CD8+ T-cell response ...
Oral sulopenem demonstrated non-inferiority to amoxicillin/clavulanate in treating uUTIs, with a 60.9% success rate versus 55.6%. Statistically significant ...
The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...
EG110A targets type C sensory neurons to manage neurogenic detrusor overactivity-related incontinence, preserving other bladder controls. Fast track designation by the FDA allows EG110A to benefit ...
Lantheus' new formulation of piflufolastat F 18 aims to increase batch size by 50% and enhance radioactive concentration, potentially expanding patient access. The original formulation was approved in ...
VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results